Clinical Trials
18 trialsNCT06889766 2026-05-15
LauT1
Centre Hospitalier Universitaire Vaudois
Phase 1 Recruiting
NCT03132922 2026-05-07
MAGE-A4ᶜ¹º³²T for Multi-Tumor
USWM, LLC (dba US WorldMeds)
Phase 1 Active not recruiting
NCT04594187 2026-02-17
MelPORT
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT04478279 2026-02-09
A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors
Sapience Therapeutics
Phase 1/2 Active not recruiting
NCT04616248 2026-01-07
In Situ Immunomodulation With CDX-301, Radiation Therapy, CDX-1140 and Poly-ICLC in Patients w/ Unresectable and Metastatic Solid Tumors
University of Southern California
Phase 1 Active not recruiting
NCT04581382 2025-07-10
Radiation Therapy, Plasma Exchange, and Immunotherapy (Pembrolizumab or Nivolumab) for the Treatment of Melanoma
Mayo Clinic
Phase EARLY_PHASE1 Completed
NCT02318771 2025-05-15
Radiation Therapy and MK-3475 for Patients With Recurrent/Metastatic Head and Neck Cancer, Renal Cell Cancer, Melanoma, and Lung Cancer
Thomas Jefferson University
Phase 1 Completed
NCT00405405 2025-05-06
Phase I of Biologics and Chemoradiation Therapy for Advanced Head and Neck Cancer
Thomas Jefferson University
Phase 1 Completed
NCT00975520 2024-11-27
RTN2
Melanoma and Skin Cancer Trials Limited
Phase NA Completed
NCT01769222 2024-01-24
Ipilimumab and Local Radiation for Selected Solid Tumors
Stanford University
Phase 1 Terminated
NCT02890368 2023-04-05
Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Solid Tumors and Mycosis Fungoides
Pfizer
Phase 1 Terminated
NCT03050060 2022-06-22
Image Guided Hypofractionated Radiation Therapy, Nelfinavir Mesylate, Pembrolizumab, Nivolumab and Atezolizumab in Treating Patients With Advanced Melanoma, Lung, or Kidney Cancer
University of Washington
Phase 2 Terminated
NCT02431572 2020-04-28
A Pilot Study to Evaluate PBR PET in Brain Tumor Patients Treated With Chemoradiation or Immunotherapy
Massachusetts General Hospital
Phase NA Completed
NCT01449279 2020-03-02
Pilot Ipilimumab in Stage IV Melanoma Receiving Palliative Radiation Therapy
Stanford University
Phase 2 Completed
NCT01996202 2019-07-05
A Pilot Study of Ipilumimab and Radiation in Poor Prognosis Melanoma
Duke University
Phase 1 Completed
NCT03220009 2018-10-03
Nivolumab or Expectant Observation Following Ipilimumab, Nivolumab, and Surgery in Treating Patients With High Risk Localized, Locoregionally Advanced, or Recurrent Mucosal Melanoma
National Cancer Institute (NCI)
Phase 2 Withdrawn
NCT00923195 2015-10-28
Radiation, Chemotherapy, Vaccine and Anti-MART-1 and Anti-gp100 Cells for Patients With Metastatic Melanoma
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT00287196 2013-06-25
Immediate Radiotherapy or Observation After Surgery for Melanoma Involving Lymph Nodes
Trans Tasman Radiation Oncology Group
Phase 3 Completed